We are pleased to announce that Eva Kovacova joined Glycanostics as our CEO as of January 2021. Eva worked more than 18 years for some of the largest pharmaceutical companies as Director Corporate Development, as well as Finance Director. She was member of the team that secured signing of 3-arm transaction between GSK and Novartis in April 2014, based on which GSK acquired the Novartis’ global Vaccines portfolio for $ 5.25bn, divested its marketed Oncology portfolio for $ 16bn and agreed to create a joint venture for their combined Consumer Healthcare products with pro forma revenues of £ 6.5bn. She led the integration project in EMEA and LATAM to create joint venture between GSK and Novartis and later between GSK and Pfizer with pro forma revenues of $ 10bn (later listed at LSE and NYSE as Haleon). She was also in charge of the carve out process of LifeScan division from Johnson & Johnson in EMEA in the value of $ 2bn. Eva brings to Glycanostics her cross-functional knowledge of the pharmaceutical industry, as well as business development and strategic leadership.

We look forward to working with her to create a highly professional company, attract key talents and gain trust of investors and grant agencies.